Evidence map›Paper›PMID 31901291›Full record

ReviewInternational journal of pediatric otorhinolaryngology2020

Panel 1: Biotechnology, biomedical engineering and new models of otitis media.

Marie Gisselsson-Solén, Paula A Tähtinen, Allen F Ryan, Apoorva Mulay, Shin Kariya, Anne G M Schilder, Tulio A Valdez, Steve Brown, Ryan M Nolan, Ann Hermansson and 2 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of pediatric otorhinolaryngology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Application of New Materials in Auditory Disease Treatment.Frontiers in cellular neuroscience · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 6 countries.

Marie Gisselsson-SolénDepartment of Clinical Sciences, Division of Otorhinolaryngology, Head and Neck Surgery, Lund University Hospital, Lund, Sweden.
Paula A TähtinenDepartment of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
Allen F RyanDivision of Otolaryngology, Department of Surgery, University of California, San Diego, La Jolla, CA, USA; San Diego Veterans Affairs Healthcare System, Research Department, San Diego, CA, USA.
Apoorva MulayThe Stripp Lab, Pulmonary Department, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Shin KariyaDepartment of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Anne G M SchilderEvidENT, Ear Institute, University College London, London, UK; National Institute for Health Research University College London Biomedical Research Centre, London, UK; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Tulio A ValdezDepartment of Otolaryngology Head & Neck Surgery, Stanford University, Palo Alto, CA, USA.
Steve BrownMRC Harwell Institute, Mammalian Genetics Unit, Harwell Campus, Oxfordshire, UK.
Ryan M NolanPhotoniCare, Inc., Champaign, IL, USA.
Ann HermanssonDepartment of Clinical Sciences, Division of Otorhinolaryngology, Head and Neck Surgery, Lund University Hospital, Lund, Sweden.
Gijs van IngenDepartment of Otolaryngology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Tal MaromDepartment of Otolaryngology-Head and Neck Surgery, Samson Assuta Ashdod University Hospital, Faculty of Health Sciences Ben Gurion University, Ashdod, Israel. Electronic address: talmarom73@gmail.com.
Lund University · SECedars-Sinai Medical Center · USErasmus MC · NLMary Lyon Centre at MRC Harwell · GBOkayama University · JPPhotoniCare (United States) · USStanford University · USTurku University Hospital · FIUniversity Medical Center Utrecht · NLUniversity of California, San Diego · US

Funding

Middle ear responses in Otitis MediaR01DC000129 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RYAN, ALLEN F. · 1989 to 2021
$6.8M
Innovative therapy for diseases of the middle earR01DC012595 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RYAN, ALLEN F. · 2012 to 2023
$3.3M
International Symposia on Recent Advances in Otitis MediaR13DC017389 · NIDCD · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BAKALETZ, LAUREN O · 2018 to 2022
$91k
Department of Health NIHR-RP-011-045NIDCD NIH HHS R01 DC000129NIDCD NIH HHS R01 DC012595NIDCD NIH HHS R13 DC017389
6 · The paper itself

Abstract

objectiveTo summarize recently published key articles on the topics of biomedical engineering, biotechnology and new models in relation to otitis media (OM). DATA SOURCES: Electronic databases: PubMed, Ovid Medline, Cochrane Library and Clinical Evidence (BMJ Publishing). REVIEW

methodsArticles on biomedical engineering, biotechnology, material science, mechanical and animal models in OM published between May 2015 and May 2019 were identified and subjected to review. A total of 132 articles were ultimately included.

resultsNew imaging technologies for the tympanic membrane (TM) and the middle ear cavity are being developed to assess TM thickness, identify biofilms and differentiate types of middle ear effusions. Artificial intelligence (AI) has been applied to train software programs to diagnose OM with a high degree of certainty. Genetically modified mice models for OM have further investigated what predisposes some individuals to OM and consequent hearing loss. New vaccine candidates protecting against major otopathogens are being explored and developed, especially combined vaccines, targeting more than one pathogen. Transcutaneous vaccination against non-typeable Haemophilus influenzae has been successfully tried in a chinchilla model. In terms of treatment, novel technologies for trans-tympanic drug delivery are entering the clinical domain. Various growth factors and grafting materials aimed at improving healing of TM perforations show promising results in animal models.

conclusionNew technologies and AI applications to improve the diagnosis of OM have shown promise in pre-clinical models and are gradually entering the clinical domain. So are novel vaccines and drug delivery approaches that may allow local treatment of OM. IMPLICATIONS FOR PRACTICE: New diagnostic methods, potential vaccine candidates and the novel trans-tympanic drug delivery show promising results, but are not yet adapted to clinical use.

Indexed as

AnimalsArtificial IntelligenceBiofilmsBiomedical EngineeringBiotechnologyDisease Models, AnimalEar, MiddleHaemophilus InfectionsHaemophilus influenzaeHaemophilus VaccinesHumansOtitis MediaOtitis Media with EffusionTympanic MembraneHaemophilus VaccinesAnimal modelDiagnosticsHaemophilus influenzaeMoraxella catarrhalisOtitis mediaStreptococcus pneumoniaeTreatmentVaccines

Identifiers

PMID31901291
PMCPMC7176743
OpenAlexW2997633615

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.